Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Hugh R Taylor a Centre for Eye Research
Australia, University of Melbourne, Locked Bag 8, East Melbourne,
Victoria, Australia, 8002, b Department of Epidemiology and Preventive Medicine, Monash
University, Room 306, Building ALF, Alfred Hospital, Caulfield,
Victoria, Australia, 3145
Correspondence to: H R Taylor h.taylor{at}unimelb.edu.au
Objective:
To determine whether vitamin E
supplementation influences the incidence or rate of progression of age
related maculopathy (AMD).
What is already known on this topic
Currently, there are no methods of prevention or treatment in most
cases, though a third of cases are due to cigarette smoking Antioxidant vitamins have been suggested as a possible prevention What this study adds
Design:
Prospective randomised placebo controlled clinical trial.
Setting:
An urban study centre in a residential area supervised by university research staff.
Participants:
1193 healthy volunteers aged between 55 and 80 years; 73% completed the trial on full protocol.
Interventions:
Vitamin E 500 IU or placebo daily for
four years.
Main outcome measures:
Primary outcome: development
of early age related macular degeneration in retinal photographs. Other
measures included alternative definitions of age related macular
degeneration, progression, changes in component features, visual
acuity, and visual function
Results:
The incidence of early age related macular degeneration (early AMD 3) was 8.6% in those receiving vitamin E
versus 8.1% in those on placebo (relative risk 1.05, 95% confidence interval 0.69 to 1.61). For late disease the incidence was 0.8% versus
0.6% (1.36, 0.67 to 2.77). Further analysis showed no consistent differences in secondary outcomes.
Conclusion:
Daily supplement with vitamin E
supplement does not prevent the development or progression of early or
later stages of age related macular degeneration.
Age related macular degeneration is the leading cause of loss of vision
and blindness in elderly people; for people aged
90 years, two out
of every three will be affected and one in four will become
blind
Daily supplementation with 500 mg vitamin E for four years did not
alter the incidence or progression of AMD
Read all Rapid Responses
What can you learn from this BMJ paper? Read Leanne Tite's Paper+